Scarica l'app Stockscreener
138.23
3.02%
-4.30
Pre-mercato:
139.01
0.78
+0.56%
Precedente Chiudi:
$142.53
Aprire:
$142.77
Volume 24 ore:
661.18K
Relative Volume:
0.76
Capitalizzazione di mercato:
$6.74B
Reddito:
-
Utile/perdita netta:
$-192.89M
Rapporto P/E:
-35.47
EPS:
-3.8976
Flusso di cassa netto:
$-172.97M
1 W Prestazione:
+0.40%
1M Prestazione:
+12.91%
6M Prestazione:
+41.77%
1 anno Prestazione:
+1,186%
Intervallo 1D:
$136.44
$142.81
Intervallo di 1 settimana:
$127.75
$142.81
Portata 52W:
$10.26
$151.02
Celcuity Inc Stock (CELC) Company Profile
Nome
Celcuity Inc
Settore
Industria
Telefono
763-392-0767
Indirizzo
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
138.23 | 6.95B | 0 | -192.89M | -172.97M | -3.8976 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | Citizens | Mkt Outperform |
| 2025-12-12 | Iniziato | Wells Fargo | Overweight |
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-11-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | Iniziato | Guggenheim | Buy |
| 2025-07-01 | Ripresa | Stifel | Buy |
| 2024-07-22 | Iniziato | Leerink Partners | Outperform |
| 2024-02-22 | Iniziato | Stifel | Buy |
| 2023-12-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-08 | Iniziato | Canaccord Genuity | Buy |
| 2021-09-07 | Iniziato | Jefferies | Buy |
| 2021-07-29 | Iniziato | Cowen | Outperform |
| 2021-07-27 | Iniziato | Needham | Buy |
| 2021-01-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-11 | Ripresa | Craig Hallum | Buy |
| 2018-11-20 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Celcuity Inc Borsa (CELC) Ultime notizie
Why is Avoro Capital Advisors Making a Big Bet on Celcuity (CELC) - Kavout
Celcuity Inc. Advances SEC Compliance and Capital Markets Goals - Faegre Drinker Biddle & Reath LLP
Price-Driven Insight from (CELC) for Rule-Based Strategy - Stock Traders Daily
Celcuity Inc. Files Amendment No. 1 to Form 8-K/A with SEC for February 2026 Event - Minichart
Celcuity’s Gedatolisib Shines Amid Mounting Cash Burn - TipRanks
Celcuity Is Maintained at Buy by HC Wainwright & Co. - Moomoo
H.C. Wainwright Maintains Celcuity(CELC.US) With Buy Rating, Raises Target Price to $185 - Moomoo
Celcuity Shareholders Approve New 2026 Equity Incentive Plans - The Globe and Mail
Celcuity: Approaching An Inflection Point With Gedatolisib (NASDAQ:CELC) - Seeking Alpha
CELC Maintained by HC Wainwright & Co. -- Price Target Raised to $185 - GuruFocus
Citizens reiterates Celcuity stock rating ahead of July approval By Investing.com - Investing.com Australia
Celcuity (CELC) price target increased by 20.06% to 159.86 - MSN
Citizens reiterates Celcuity stock rating ahead of July approval - Investing.com UK
Celcuity stock price target raised to $185 by H.C. Wainwright - Investing.com UK
Celcuity stock price target raised to $185 by H.C. Wainwright By Investing.com - Investing.com Australia
UBS Group AG Reduces Stock Position in Celcuity, Inc. $CELC - MarketBeat
Celcuity Price Target Raised to $185.00/Share From $165.00 by HC Wainwright & Co. - Moomoo
Why Celcuity (CELC) Is Up 5.1% After VIKTORIA-1 Success And Pipeline ExpansionAnd What's Next - Sahm
Celcuity outlines VIKTORIA-2 expansion while targeting July 17 FDA decision for gedatolisib - MSN
LifeSci Capital Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $165 - Moomoo
Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst - Sahm
Celcuity (CELC) Gets a Buy from Stifel Nicolaus - The Globe and Mail
Celcuity Inc. (NASDAQ:CELC) Q1 2026 Earnings Call Transcript - Insider Monkey
Assessing Celcuity (CELC) Valuation After Positive VIKTORIA 1 Data And Upcoming FDA Decision - Yahoo Finance
Celcuity Q1 earnings call highlights - MSN
Celcuity’s Earnings Call: Strong Data, Rising Cash Burn - TipRanks
Celcuity (NASDAQ:CELC) Posts Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Stifel raises Celcuity stock price target on trial expansion potential - Investing.com UK
Celcuity's cancer drug expansion could ignite massive new market opportunity: Analyst - MSN
Analysts Are Bullish on Top Healthcare Stocks: Celcuity (CELC), Rubicon Organics (ROMJF) - The Globe and Mail
What's Going On With Celcuity Stock Friday?Celcuity (NASDAQ:CELC) - Benzinga
Stifel raises Celcuity stock price target on trial expansion potential By Investing.com - Investing.com Australia
Stifel Maintains Celcuity(CELC.US) With Buy Rating, Raises Target Price to $175 - Moomoo
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $157 to $183 - Moomoo
Celcuity Inc. Stock 12‑Month Price Target Raised to $167.18, Implies 24% Upside - TradingView
Celcuity Inc. Stock 12‑Month Price Target Raised to $164, Implies 22% Upside - TradingView
Celcuity Inc. Stock 12‑Month Price Target Raised to $159, Implies 18% Upside - TradingView
Celcuity Q1 2026 Earnings Call Transcript - MarketBeat
Celcuity Q1 Earnings Call Highlights - sharewise.com
CELC: Positive phase III data and commercial launch readiness mark a pivotal Q1 2026 - TradingView
Celcuity (CELC) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings call transcript: Celcuity’s Q1 2026 results beat expectations - Investing.com
Earnings call transcript: Celcuity’s Q1 2026 results beat expectations By Investing.com - Investing.com Canada
Transcript: Celcuity Q1 2026 Earnings Conference Call - Benzinga
Celcuity Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Celcuity Inc. (NASDAQ:CELC) Q1 Earnings Beat Forecasts, But Stock Drops on Phase 3 Data Focus - ChartMill
Celcuity posts narrower-than-feared Q1 loss By Investing.com - Investing.com South Africa
CELCUITY ($CELC) Releases Q1 2026 Earnings - Quiver Quantitative
Celcuity Inc Azioni (CELC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):